GLUCOSAMINE SAVES JOINTS: New
Trial Finds Measurable Arthritis Improvement
The following article reports the
now scientifically "proven" effects of glucosamine on arthritis, what
many have now known and experienced for a few years now.
By Adam Marcus HealthScout Reporter
THURSDAY, Jan. 25, 2001 (HealthScout) -- In what one arthritis expert
calls a "landmark" study, researchers say regular treatment with
glucosamine can ease the pain, swelling and stiffness of osteoarthritis
and lead to measurable improvements in joints.
Glucosamine is a natural supplement whose advocates claim it relieves
the symptoms of osteoarthritis, a cartilage-eroding ailment that strikes
roughly one in three Americans over age 63. However, few reliable
studies have found any benefit from the treatment until now.
In the latest study, reported in the upcoming issue of The Lancet, a
team led by Dr. Jean Yves Reginster of the Bone and Cartilage Metabolism
Unit of the CHU Centre Ville in Liege, Belgium, tested the supplement on
212 people with osteoarthritis in their knees. Subjects were given
either a dummy drug or 1,500 milligrams of glucosamine daily over three
The patients had their knee joints X-rayed at the beginning and the end
of the trial to measure how much protective cartilage shielded their
joints from friction and impact.
By the end of the study, patients on glucosamine reported a 20 percent
to 25 percent improvement of their symptoms, while the placebo group
reported slight deterioration. The X-rays showed that joint spaces in
the untreated patients had narrowed by an average of 20 millimeters,
compared to no change among those who took glucosamine.
Reginster says, "We demonstrate that we have significant differences in
the number of patients who experienced a significant, relevant loss" in
their joint space. "It's the first [study] that shows that it's possible
to demonstrate an effect both on the symptoms and the structure" of
joints, says Reginster. He says a recent Czech study found similar
Not sure how it works
The study, which was first reported at a 1999 meeting of arthritis
experts, was sponsored by the Rorta Research Group, an Italian company
that makes much of the glucosamine available in Europe. While several
European countries have officially approved glucosamine as an arthritis
remedy, the compound is available in the United States only as an
Reginster says that's problematic because different versions of the
product vary widely in the amount of the active chemical.
Dr. John Klippel, medical director of the Arthritis Foundation, says The
Lancet paper should have an "extraordinary" impact on the treatment of
osteoarthritis. "I think this is a landmark study of major importance."
Klippel says not only does it show symptom relief, but it offers
evidence that glucosamine leads to beneficial physiological changes.
What the work doesn't explain, however, is how glucosamine works with
arthritis. Glucosamine is a building block of cartilage, and some
experts have proposed that it might spur formation of new cartilage in
affected joints. But so far no one has proven that, he says.
Many patients in the Belgian study reported improvement within about a
month of starting treatment, suggesting glucosamine might have
anti-inflammatory properties, Klippel says.
Interviews with Jean Yves Reginster, M.D., Ph.D., Bone and Cartilage
Metabolism Unit, University Hospital, Liege, Belgium; John Klippel,
M.D., medical director, Arthritis Foundation, Washington, D.C.; Jan. 27,
2001, The Lancet
Long-term Effects of Glucosamine Sulphate on Osteoarthritis Progression:
A Randomised, Placebo-controlled Clinical Trial - Lancet 2001 Jan 27;
357 (9252): Unlisted page numbers